diazoxide has been researched along with Obesity in 56 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In DESTINY PWS, a 13-week, randomized, double-blind, placebo-controlled, phase 3 trial, 127 participants with PWS aged 4 years and older with hyperphagia were randomly assigned 2:1 to diazoxide choline extended-release tablet (DCCR) or placebo." | 9.69 | Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. ( Abuzzahab, J; Angulo, M; Barrett, T; Bhatnagar, A; Bird, LM; Bridges, N; Butler, MG; Cowen, NM; Felner, EI; Gevers, E; Lah, M; Littlejohn, E; Mathew, V; Miller, JL; Obrynba, KS; Salehi, P; Shoemaker, AH; Stevenson, D; Yanovski, JA, 2023) |
| "Proof-of-concept study to investigate the amplifying effects of diazoxide (DZX)-mediated insulin suppression on lifestyle-induced weight loss in nondiabetic, hyperinsulinemic, obese men." | 9.27 | High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention. ( Brandon, T; de Boer, H; Filius, M; Hermus, A; Loves, S; Mekking, M; Tack, CJ; van Groningen, L, 2018) |
| "We conducted a pilot project to test the hypothesis that decreasing insulin concentrations with diazoxide would affect parameters of vitamin D in obese women with and without polycystic ovary syndrome (PCOS)." | 9.16 | A pilot study: effects of decreasing serum insulin with diazoxide on vitamin D levels in obese women with polycystic ovary syndrome. ( Bachmann, LM; Cheang, KI; Downs, RW; Nestler, JE; Reilly, ER, 2012) |
| "Obese women with polycystic ovary syndrome (PCOS) manifest impaired insulin-stimulated release of a d-chiro-inositol-containing inositolphosphoglycan (DCI-IPG) insulin mediator during oral glucose tolerance testing (OGTT), which appears to be restored by the administration of metformin." | 9.14 | Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. ( Apridonidze, T; Baillargeon, JP; Iuorno, MJ; Nestler, JE, 2010) |
| " The aim of the present study was to investigate the effect of inhibition of insulin secretion by diazoxide on weight loss in obese, normoglycaemic (fasting plasma glucose of > or =6." | 9.12 | No effect of inhibition of insulin secretion by diazoxide on weight loss in hyperinsulinaemic obese subjects during an 8-week weight-loss diet. ( Astrup, A; Due, A; Eriksen, G; Flint, A; Hansen, JB; Møller, B; Raben, A, 2007) |
| "To examine the concept whether high-dose diazoxide (DZX)-mediated insulin suppression, in combination with moderate caloric restriction and increased physical activity, can establish a weight loss of at least 15% in obese hyperinsulinaemic men." | 7.74 | Weight loss in obese men by caloric restriction and high-dose diazoxide-mediated insulin suppression. ( de Boer, H; Loves, S; Rijnders, T; Ruinemans-Koerts, J; van Boekel, G; van Sorge, A, 2008) |
| "To test the hypothesis that insulin plays a role in the hyperandrogenism of obese women with polycystic ovary syndrome, we conducted a prospective study in which the androgen status of five obese women with polycystic ovary syndrome was assessed on two occasions: before and after 10 days of oral diazoxide (100 mg, three times daily) administration." | 7.67 | Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. ( Barlascini, CO; Blackard, WG; Clore, JN; Matt, DW; Nestler, JE; Plymate, SR; Steingold, KA, 1989) |
| " The most common adverse events were peripheral edema and transient increases in glucose." | 6.90 | A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome. ( Cowen, NM; Gold, JA; Kimonis, V; Surampalli, A; Wencel, M, 2019) |
| "In DESTINY PWS, a 13-week, randomized, double-blind, placebo-controlled, phase 3 trial, 127 participants with PWS aged 4 years and older with hyperphagia were randomly assigned 2:1 to diazoxide choline extended-release tablet (DCCR) or placebo." | 5.69 | Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. ( Abuzzahab, J; Angulo, M; Barrett, T; Bhatnagar, A; Bird, LM; Bridges, N; Butler, MG; Cowen, NM; Felner, EI; Gevers, E; Lah, M; Littlejohn, E; Mathew, V; Miller, JL; Obrynba, KS; Salehi, P; Shoemaker, AH; Stevenson, D; Yanovski, JA, 2023) |
| "Treatment with diazoxide partially normalizes obesity in children and adults with PWS and in a PWS mouse model, demonstrating that the biological pathways impacted by diazoxide may be rational pharmacological targets in PWS and other disorders diseases associated with obesity." | 5.48 | Chronic diazoxide treatment decreases fat mass and improves endurance capacity in an obese mouse model of Prader-Willi syndrome. ( Bischof, JM; Wevrick, R, 2018) |
| "Obesity is associated with increased infarct volumes and adverse outcomes following ischemic stroke." | 5.40 | Sevoflurane postconditioning against cerebral ischemic neuronal injury is abolished in diet-induced obesity: role of brain mitochondrial KATP channels. ( Chen, Y; Fang, X; Jiang, Y; Xu, J; Yang, Z; Zhang, Y, 2014) |
| "Diazoxide-treated obese and lean animals showed significantly lower postabsorptive plasma insulin concentrations (P < 0." | 5.29 | Modification of insulin resistance by diazoxide in obese Zucker rats. ( Alemzadeh, R; Maturo, J; Slonim, AE; Zdanowicz, MM, 1993) |
| "It has been suggested that stimulation of lipolysis by diazoxide (DZX)-mediated insulin suppression may be useful in treating obesity." | 5.27 | Effects of Diazoxide-Mediated Insulin Suppression on Glucose and Lipid Metabolism in Nondiabetic Obese Men. ( Brandon, T; de Boer, H; Filius, M; Hermus, A; Loves, S; Mekking, M; Tack, CJ; van Groningen, L, 2018) |
| "Proof-of-concept study to investigate the amplifying effects of diazoxide (DZX)-mediated insulin suppression on lifestyle-induced weight loss in nondiabetic, hyperinsulinemic, obese men." | 5.27 | High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention. ( Brandon, T; de Boer, H; Filius, M; Hermus, A; Loves, S; Mekking, M; Tack, CJ; van Groningen, L, 2018) |
| "We conducted a pilot project to test the hypothesis that decreasing insulin concentrations with diazoxide would affect parameters of vitamin D in obese women with and without polycystic ovary syndrome (PCOS)." | 5.16 | A pilot study: effects of decreasing serum insulin with diazoxide on vitamin D levels in obese women with polycystic ovary syndrome. ( Bachmann, LM; Cheang, KI; Downs, RW; Nestler, JE; Reilly, ER, 2012) |
| "Obese women with polycystic ovary syndrome (PCOS) manifest impaired insulin-stimulated release of a d-chiro-inositol-containing inositolphosphoglycan (DCI-IPG) insulin mediator during oral glucose tolerance testing (OGTT), which appears to be restored by the administration of metformin." | 5.14 | Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. ( Apridonidze, T; Baillargeon, JP; Iuorno, MJ; Nestler, JE, 2010) |
| " The aim of the present study was to investigate the effect of inhibition of insulin secretion by diazoxide on weight loss in obese, normoglycaemic (fasting plasma glucose of > or =6." | 5.12 | No effect of inhibition of insulin secretion by diazoxide on weight loss in hyperinsulinaemic obese subjects during an 8-week weight-loss diet. ( Astrup, A; Due, A; Eriksen, G; Flint, A; Hansen, JB; Møller, B; Raben, A, 2007) |
| "Persistent suppression of hyperinsulinemia in genetically obese (fa/fa) Zucker rats by diazoxide (DZ) reduces food intake and weight gain; improves insulin sensitivity, glycemic control, and lipid profile; and enhances beta(3)-adrenergic function and lipolysis in adipose tissue." | 3.74 | Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats. ( Alemzadeh, R; Buchholz, M; Karlstad, MD; Tushaus, K, 2008) |
| "To examine the concept whether high-dose diazoxide (DZX)-mediated insulin suppression, in combination with moderate caloric restriction and increased physical activity, can establish a weight loss of at least 15% in obese hyperinsulinaemic men." | 3.74 | Weight loss in obese men by caloric restriction and high-dose diazoxide-mediated insulin suppression. ( de Boer, H; Loves, S; Rijnders, T; Ruinemans-Koerts, J; van Boekel, G; van Sorge, A, 2008) |
| "We have previously reported that attenuation of hyperinsulinemia by diazoxide (DZ), an inhibitor of glucose-mediated insulin secretion, increased insulin sensitivity and reduced body weight in obese Zucker rats." | 3.70 | Diazoxide down-regulates leptin and lipid metabolizing enzymes in adipose tissue of Zucker rats. ( Alemzadeh, R; Koontz, J; Moustaid-Moussa, N; Standridge, M; Zemel, M, 2000) |
| "To test the hypothesis that insulin plays a role in the hyperandrogenism of obese women with polycystic ovary syndrome, we conducted a prospective study in which the androgen status of five obese women with polycystic ovary syndrome was assessed on two occasions: before and after 10 days of oral diazoxide (100 mg, three times daily) administration." | 3.67 | Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. ( Barlascini, CO; Blackard, WG; Clore, JN; Matt, DW; Nestler, JE; Plymate, SR; Steingold, KA, 1989) |
| "Insulin binding to monocytes was assessed before and after plasma insulin suppression by diazoxide in 14 obesity-related diabetic subjects." | 3.66 | Role of insulin receptors in obesity-related diabetes. ( Blackard, WG; Taylon, A, 1982) |
| "In an attempt to determine whether the decreased number of insulin's receptors in obesity is a result of downregulation of the receptors, diazoxide (5 mg/kg/d) was given to 10 obese subjects." | 3.66 | Downregulation of insulin receptors in obese man. ( Blackard, WG; Wigand, JP, 1979) |
| " The most common adverse events were peripheral edema and transient increases in glucose." | 2.90 | A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome. ( Cowen, NM; Gold, JA; Kimonis, V; Surampalli, A; Wencel, M, 2019) |
| "The role of hyperinsulinemia as a possible preceding event in the development of obesity has been proposed." | 2.69 | Beneficial effect of diazoxide in obese hyperinsulinemic adults. ( Alemzadeh, R; Langley, G; Slonim, AE; Smith, P; Upchurch, L, 1998) |
| "Diazoxide treatment for 10 days was sufficient to increase pulsatile GH secretion in DIO mice before any significant body weight change." | 1.62 | Suppression of hyperinsulinemia restores growth hormone secretion and metabolism in obese mice. ( Chen, C; Chen, Y; Huang, L; Huang, Z; Lu, X; Veldhuis, JD; Zhang, C, 2021) |
| "Treatment with diazoxide partially normalizes obesity in children and adults with PWS and in a PWS mouse model, demonstrating that the biological pathways impacted by diazoxide may be rational pharmacological targets in PWS and other disorders diseases associated with obesity." | 1.48 | Chronic diazoxide treatment decreases fat mass and improves endurance capacity in an obese mouse model of Prader-Willi syndrome. ( Bischof, JM; Wevrick, R, 2018) |
| "Obesity is associated with increased infarct volumes and adverse outcomes following ischemic stroke." | 1.40 | Sevoflurane postconditioning against cerebral ischemic neuronal injury is abolished in diet-induced obesity: role of brain mitochondrial KATP channels. ( Chen, Y; Fang, X; Jiang, Y; Xu, J; Yang, Z; Zhang, Y, 2014) |
| "Chronic attenuation of hyperinsulinemia by diazoxide (DZ), an inhibitor of glucose-mediated insulin secretion, improved insulin sensitivity and glucose tolerance and caused down-regulation of lipid metabolizing enzymes in adipose tissue and decreased the rate of weight gain in mildly hyperglycemic obese Zucker rats." | 1.31 | Chronic suppression of insulin by diazoxide alters the activities of key enzymes regulating hepatic gluconeogenesis in Zucker rats. ( Alemzadeh, R; Holshouser, S; Koontz, J; Massey, P, 2002) |
| "Diazoxide treatment increased estradiol levels in controls, but not in obese men." | 1.29 | Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. ( Biscotti, M; Boschi, S; Casimirri, F; Chierici, R; De Iasio, R; Flamia, R; Mesini, P; Pasquali, R; Vicennati, V, 1995) |
| "Diazoxide-treated obese and lean animals showed significantly lower postabsorptive plasma insulin concentrations (P < 0." | 1.29 | Modification of insulin resistance by diazoxide in obese Zucker rats. ( Alemzadeh, R; Maturo, J; Slonim, AE; Zdanowicz, MM, 1993) |
| "Mannoheptulose did not inhibit insulin secretion from fa/fa islets, although inhibitors of later events in the stimulus-secretion coupling pathway were normally inhibited by iodoacetate and diazoxide." | 1.29 | Evidence for defective glucose sensing by islets of fa/fa obese Zucker rats. ( Chan, CB; MacPhail, RM; Mitton, K, 1993) |
| "Obesity was induced by aurothioglucose." | 1.29 | Amyloid formation in response to beta cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. ( Arora, MB; Carroll, R; Chan, SJ; Fox, N; Steiner, DF; Westermark, G; Westermark, P, 1995) |
| "Diazoxide treatment resulted in suppressed insulin release during a 100-g oral glucose tolerance test (insulin area under the curve, 262 +/- 55 nmol/min." | 1.28 | A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. ( Blackard, WG; Clore, JN; Matt, DW; Nestler, JE; Plymate, SR; Powers, LP; Rittmaster, RS; Steingold, KA, 1991) |
| "Diazoxide treatment resulted in a significant suppression of glucose-stimulated early (insulin area 0-30 min) (P less than 0." | 1.27 | Effect of pharmacological suppression of insulin secretion on tissue sensitivity to insulin in subjects with moderate obesity. ( Kohnert, KD; Ratzmann, KP; Ruhnke, R, 1983) |
| "In five patients with islet cell tumors and fasting hypoglycemia, basal proinsulin-like component ranged from 26 to 79% of the total immunoreactive insulin." | 1.25 | Proinsulin-like component of circulating insulin in the basal state and in patients and hamsters with islet cell tumors. ( Gorden, P; Roth, J; Sherman, B, 1971) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (35.71) | 18.7374 |
| 1990's | 13 (23.21) | 18.2507 |
| 2000's | 14 (25.00) | 29.6817 |
| 2010's | 7 (12.50) | 24.3611 |
| 2020's | 2 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, JL | 1 |
| Gevers, E | 1 |
| Bridges, N | 1 |
| Yanovski, JA | 1 |
| Salehi, P | 1 |
| Obrynba, KS | 1 |
| Felner, EI | 1 |
| Bird, LM | 1 |
| Shoemaker, AH | 1 |
| Angulo, M | 1 |
| Butler, MG | 1 |
| Stevenson, D | 1 |
| Abuzzahab, J | 1 |
| Barrett, T | 1 |
| Lah, M | 1 |
| Littlejohn, E | 1 |
| Mathew, V | 1 |
| Cowen, NM | 2 |
| Bhatnagar, A | 1 |
| Kimonis, V | 1 |
| Surampalli, A | 1 |
| Wencel, M | 1 |
| Gold, JA | 1 |
| Huang, Z | 1 |
| Lu, X | 1 |
| Huang, L | 1 |
| Chen, Y | 2 |
| Zhang, C | 1 |
| Veldhuis, JD | 1 |
| Chen, C | 1 |
| Bischof, JM | 1 |
| Wevrick, R | 1 |
| Loves, S | 3 |
| van Groningen, L | 2 |
| Filius, M | 2 |
| Mekking, M | 2 |
| Brandon, T | 2 |
| Tack, CJ | 2 |
| Hermus, A | 2 |
| de Boer, H | 4 |
| Yang, Z | 1 |
| Zhang, Y | 1 |
| Jiang, Y | 1 |
| Fang, X | 1 |
| Xu, J | 1 |
| Alemzadeh, R | 8 |
| Karlstad, MD | 1 |
| Tushaus, K | 1 |
| Buchholz, M | 1 |
| Katakam, PV | 2 |
| Domoki, F | 1 |
| Snipes, JA | 2 |
| Busija, AR | 1 |
| Jarajapu, YP | 1 |
| Busija, DW | 2 |
| Spanakis, E | 1 |
| Gragnoli, C | 1 |
| Baillargeon, JP | 1 |
| Iuorno, MJ | 1 |
| Apridonidze, T | 1 |
| Nestler, JE | 4 |
| Reilly, ER | 1 |
| Cheang, KI | 1 |
| Bachmann, LM | 1 |
| Downs, RW | 1 |
| Guldstrand, M | 1 |
| Grill, V | 1 |
| Björklund, A | 1 |
| Lins, PE | 1 |
| Adamson, U | 1 |
| Tushaus, KM | 1 |
| Schreuder, T | 1 |
| Karreman, M | 1 |
| Rennings, A | 1 |
| Ruinemans-Koerts, J | 2 |
| Jansen, M | 1 |
| Hansen, JB | 2 |
| Jordan, JE | 1 |
| Tulbert, CD | 1 |
| Miller, AW | 1 |
| Grassiolli, S | 1 |
| Bonfleur, ML | 1 |
| Scomparin, DX | 1 |
| de Freitas Mathias, PC | 1 |
| Due, A | 1 |
| Flint, A | 1 |
| Eriksen, G | 1 |
| Møller, B | 1 |
| Raben, A | 1 |
| Astrup, A | 1 |
| van Boekel, G | 1 |
| van Sorge, A | 1 |
| Rijnders, T | 1 |
| Ratzmann, KP | 1 |
| Ruhnke, R | 1 |
| Kohnert, KD | 1 |
| Taylon, A | 1 |
| Blackard, WG | 5 |
| Marugo, M | 2 |
| Mortara, R | 1 |
| Baiardi, M | 1 |
| Giusti, M | 2 |
| Motta, A | 1 |
| Grimaldi, GP | 1 |
| Sato, Y | 2 |
| Aizawa, T | 2 |
| Taguchi, N | 2 |
| Ishihara, F | 2 |
| Hashizume, K | 2 |
| Nakabayashi, T | 1 |
| Kobuchi, H | 1 |
| Hidaka, H | 1 |
| Nagasawa, T | 1 |
| Itoh, N | 1 |
| Pasquali, R | 1 |
| Casimirri, F | 1 |
| De Iasio, R | 1 |
| Mesini, P | 1 |
| Boschi, S | 1 |
| Chierici, R | 1 |
| Flamia, R | 1 |
| Biscotti, M | 1 |
| Vicennati, V | 1 |
| Slonim, AE | 2 |
| Zdanowicz, MM | 1 |
| Maturo, J | 1 |
| Chan, CB | 2 |
| MacPhail, RM | 2 |
| Mitton, K | 1 |
| Westermark, G | 1 |
| Arora, MB | 1 |
| Fox, N | 1 |
| Carroll, R | 1 |
| Chan, SJ | 1 |
| Westermark, P | 1 |
| Steiner, DF | 1 |
| Jacobs, W | 1 |
| Pitukcheewanont, P | 1 |
| Langley, G | 1 |
| Upchurch, L | 1 |
| Smith, P | 1 |
| Picard, F | 1 |
| Naïmi, N | 1 |
| Richard, D | 1 |
| Deshaies, Y | 1 |
| Holshouser, S | 2 |
| Zhou, YP | 1 |
| Cockburn, BN | 1 |
| Pugh, W | 1 |
| Polonsky, KS | 1 |
| Standridge, M | 1 |
| Zemel, M | 1 |
| Koontz, J | 2 |
| Moustaid-Moussa, N | 1 |
| Surwit, RS | 1 |
| Dixon, TM | 1 |
| Petro, AE | 1 |
| Daniel, KW | 1 |
| Collins, S | 1 |
| Massey, P | 1 |
| Guzelian, PS | 1 |
| Small, EE | 1 |
| Wigand, JP | 1 |
| Cocco, R | 1 |
| Bolognesi, F | 1 |
| Reitano, A | 1 |
| Powers, LP | 1 |
| Matt, DW | 2 |
| Steingold, KA | 2 |
| Plymate, SR | 2 |
| Rittmaster, RS | 1 |
| Clore, JN | 2 |
| Barlascini, CO | 1 |
| Hellman, B | 7 |
| Idahl, LA | 2 |
| Loyau, G | 1 |
| Kopp, J | 1 |
| Sauvalle, A | 1 |
| Porin, J | 1 |
| Sehlin, J | 5 |
| Täljedal, IB | 4 |
| Gorden, P | 1 |
| Sherman, B | 1 |
| Roth, J | 1 |
| Lernmark, A | 1 |
| Mirouze, J | 1 |
| Jaffiol, C | 1 |
| Mary, P | 1 |
| Taylor, KW | 1 |
| Raptis, S | 1 |
| Schröder, KE | 1 |
| Faulhaber, JD | 1 |
| Pfeiffer, EF | 1 |
| Danielsson, A | 1 |
| Täljedal, I | 1 |
| Townley, RG | 1 |
| Daley, D | 1 |
| Selenke, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diazoxide-mediated Insulin Suppression in Hyperinsulinemic Obese Men, Part III[NCT00631033] | Phase 2 | 51 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Is There An Association Between Vitamin D Levels And Insulin Resistance In Polycystic Ovary Syndrome?[NCT02803476] | 166 participants (Anticipated) | Observational | 2016-03-31 | Recruiting | |||
| Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men: a Dose Response Study, Part II[NCT00151684] | Phase 2 | 25 participants (Anticipated) | Interventional | 2004-11-30 | Completed | ||
| Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome[NCT00784615] | 80 participants (Anticipated) | Observational | 2007-12-31 | Recruiting | |||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for diazoxide and Obesity
| Article | Year |
|---|---|
Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives.
Topics: Amides; Animals; ATP-Binding Cassette Transporters; Benzopyrans; Benzothiadiazines; Congenital Hyper | 2006 |
10 trials available for diazoxide and Obesity
| Article | Year |
|---|---|
Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.
Topics: COVID-19; Diazoxide; Humans; Hyperphagia; Obesity; Prader-Willi Syndrome | 2023 |
A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome.
Topics: Adolescent; Basal Metabolism; Body Composition; Child; Delayed-Action Preparations; Diazoxide; Doubl | 2019 |
Effects of Diazoxide-Mediated Insulin Suppression on Glucose and Lipid Metabolism in Nondiabetic Obese Men.
Topics: Adult; Blood Glucose; Body Mass Index; Caloric Restriction; Diazoxide; Double-Blind Method; Exercise | 2018 |
High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Diazoxide; Dose-Response Relationship, Drug; Dou | 2018 |
Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.
Topics: Adolescent; Adult; Case-Control Studies; Cross-Sectional Studies; Diazoxide; Female; Glucose Clamp T | 2010 |
A pilot study: effects of decreasing serum insulin with diazoxide on vitamin D levels in obese women with polycystic ovary syndrome.
Topics: Administration, Oral; Adult; Androgens; Blood Glucose; Body Weight; Comorbidity; Diazoxide; Dose-Res | 2012 |
Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes.
Topics: Antihypertensive Agents; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, LDL; Diabetes Mellitus; | 2002 |
Diazoxide-mediated insulin suppression in obese men: a dose-response study.
Topics: Adult; Area Under Curve; Blood Glucose; Body Weight; Depression, Chemical; Diazoxide; Diuretics; Dos | 2005 |
No effect of inhibition of insulin secretion by diazoxide on weight loss in hyperinsulinaemic obese subjects during an 8-week weight-loss diet.
Topics: Adult; Blood Glucose; C-Peptide; Counseling; Diazoxide; Diet, Reducing; Double-Blind Method; Energy | 2007 |
Beneficial effect of diazoxide in obese hyperinsulinemic adults.
Topics: Adult; Body Composition; Body Mass Index; Body Weight; Diazoxide; Diet, Reducing; Energy Intake; Fem | 1998 |
45 other studies available for diazoxide and Obesity
| Article | Year |
|---|---|
Suppression of hyperinsulinemia restores growth hormone secretion and metabolism in obese mice.
Topics: Animals; Body Composition; Diazoxide; Diet, High-Fat; Energy Metabolism; Growth Hormone; Hyperinsuli | 2021 |
Chronic diazoxide treatment decreases fat mass and improves endurance capacity in an obese mouse model of Prader-Willi syndrome.
Topics: Animals; Antigens, Neoplasm; Antihypertensive Agents; Body Fat Distribution; Diazoxide; Diet, High-F | 2018 |
Sevoflurane postconditioning against cerebral ischemic neuronal injury is abolished in diet-induced obesity: role of brain mitochondrial KATP channels.
Topics: Animals; Body Weight; Brain; Brain Injuries; Brain Ischemia; Decanoic Acids; Diazoxide; Diet, High-F | 2014 |
Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats.
Topics: Adenylyl Cyclases; Animals; Basal Metabolism; Blood Glucose; Body Composition; Calorimetry, Indirect | 2008 |
Impaired mitochondria-dependent vasodilation in cerebral arteries of Zucker obese rats with insulin resistance.
Topics: Animals; Cerebral Arteries; Cyclooxygenase Inhibitors; Diazoxide; Disease Models, Animal; Dose-Respo | 2009 |
Successful medical management of status post-Roux-en-Y-gastric-bypass hyperinsulinemic hypoglycemia.
Topics: Antihypertensive Agents; Diazoxide; Female; Gastric Bypass; Humans; Hyperinsulinism; Hypoglycemia; M | 2009 |
Modulation of adipoinsular axis in prediabetic zucker diabetic fatty rats by diazoxide.
Topics: Adenylyl Cyclases; Adiponectin; Adipose Tissue; Animals; Blood Glucose; Body Weight; Diabetes Mellit | 2004 |
Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance.
Topics: Animals; Decanoic Acids; Diazoxide; Hydroxy Acids; Immunoblotting; In Vitro Techniques; Insulin Resi | 2007 |
Pancreatic islets from hypothalamic obese rats maintain K+ATP channel-dependent but not -independent pathways on glucose-induced insulin release process.
Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Diazoxide; Glucose; Hypothalamus; Insulin; Insuli | 2006 |
Weight loss in obese men by caloric restriction and high-dose diazoxide-mediated insulin suppression.
Topics: Adult; Body Composition; Caloric Restriction; Diazoxide; Diet, Reducing; Dose-Response Relationship, | 2008 |
Effect of pharmacological suppression of insulin secretion on tissue sensitivity to insulin in subjects with moderate obesity.
Topics: Adipose Tissue; Adult; Blood Glucose; Diazoxide; Humans; Insulin; Insulin Secretion; Middle Aged; Ob | 1983 |
Role of insulin receptors in obesity-related diabetes.
Topics: Adult; Diabetes Mellitus; Diazoxide; Female; Humans; Insulin; Middle Aged; Monocytes; Obesity; Recep | 1982 |
[Evaluation of the metabolic action of glucagon in subjects undergoing anti-insulin therapy].
Topics: Adult; Blood Glucose; Diazoxide; Glucagon; Growth Hormone; Humans; Hyperinsulinism; Insulin; Lipids; | 1981 |
Glucose-induced insulin release by pancreatic islets is enhanced in rats with naturally occurring obese non-insulin-dependent diabetes.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diazoxide; Diuretics; Glucose; Glucose Tolera | 1995 |
Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diazoxide; Di | 1995 |
Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men.
Topics: Adult; Body Weight; Diazoxide; Glucose Tolerance Test; Gonadal Steroid Hormones; Gonadotropins; Huma | 1995 |
Modification of insulin resistance by diazoxide in obese Zucker rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Diazoxide; Energy Intake; Female; Glucose Tolerance Test; In | 1993 |
Evidence for defective glucose sensing by islets of fa/fa obese Zucker rats.
Topics: Adenosine Triphosphate; Amino Acids; Animals; Blood Glucose; Diazoxide; Female; Glucokinase; Glucose | 1993 |
Amyloid formation in response to beta cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide.
Topics: Amyloid; Animals; Antihypertensive Agents; Aurothioglucose; Blood Glucose; Cells, Cultured; Cortison | 1995 |
Antiobesity effect of diazoxide in obese Zucker rats.
Topics: Adipocytes; Animals; Blood Glucose; Diazoxide; Energy Intake; Female; Glucose; Insulin; Lipids; Lipo | 1996 |
KATP channel-dependent and -independent pathways of insulin secretion in isolated islets from fa/fa Zucker rats.
Topics: Adenosine Triphosphate; Animals; Diazoxide; Dose-Response Relationship, Drug; Female; Glucose; Insul | 1996 |
Response of adipose tissue lipoprotein lipase to the cephalic phase of insulin secretion.
Topics: Adipose Tissue; Animals; Blood Glucose; Diazoxide; Dietary Carbohydrates; Epididymis; Fatty Acids, N | 1999 |
Effect of diazoxide on brain capillary insulin receptor binding and food intake in hyperphagic obese Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Brain; Capillaries; Diazoxide; Eating; Fasting; Female; Hyperph | 1999 |
Basal insulin hypersecretion in insulin-resistant Zucker diabetic and Zucker fatty rats: role of enhanced fuel metabolism.
Topics: Animals; Blood Glucose; Calcium Channel Blockers; Diabetes Mellitus; Diazoxide; Enzyme Inhibitors; G | 1999 |
Diazoxide down-regulates leptin and lipid metabolizing enzymes in adipose tissue of Zucker rats.
Topics: 3T3 Cells; Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Diazoxide; Fatty Acid S | 2000 |
Diazoxide restores beta3-adrenergic receptor function in diet-induced obesity and diabetes.
Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diazoxide; Diet; | 2000 |
Chronic suppression of insulin by diazoxide alters the activities of key enzymes regulating hepatic gluconeogenesis in Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Diazoxide; Eating; Female; Glucokinase; Gluconeogenesis; Glucos | 2002 |
Down regulation of insulin receptors.
Topics: Animals; Concanavalin A; Culture Techniques; Cyclic AMP; Diazoxide; Homeostasis; Humans; Hyperinsuli | 1979 |
Downregulation of insulin receptors in obese man.
Topics: Adolescent; Adult; Diazoxide; Glucose Tolerance Test; Humans; Insulin; Kinetics; Male; Monocytes; Ob | 1979 |
[Diazoxide in the treatment of obesity].
Topics: Diazoxide; Dietary Proteins; Fenfluramine; Furosemide; Glucagon; Humans; Obesity; Triiodothyronine | 1977 |
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstane-3,17-diol; Androstenedione; Diazoxide; Estradiol; Estrone; Female; Glucose Toleran | 1991 |
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstane-3,17-diol; Androstenedione; Diazoxide; Estradiol; Estrone; Female; Glucose Toleran | 1991 |
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstane-3,17-diol; Androstenedione; Diazoxide; Estradiol; Estrone; Female; Glucose Toleran | 1991 |
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstane-3,17-diol; Androstenedione; Diazoxide; Estradiol; Estrone; Female; Glucose Toleran | 1991 |
Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome.
Topics: Blood Glucose; Diazoxide; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Huma | 1989 |
[Control of ATP levels in stimulated pancreatic B-cells].
Topics: Adenosine Triphosphate; Animals; Butyrates; Carbutamide; Cyclic AMP; Diazoxide; Epinephrine; Glucago | 1969 |
[Continuous treatment with diazoxide of hypoglycemia due to hyperinsulinism].
Topics: Aged; Diazoxide; Female; Humans; Hyperinsulinism; Hypoglycemia; Mental Disorders; Obesity | 1970 |
Transport of -aminoisobutyric acid in mammalian pancretic -cells.
Topics: Alanine; Amino Acids; Aminoisobutyric Acids; Animals; Biological Transport; Butyrates; Cyclic AMP; D | 1971 |
Proinsulin-like component of circulating insulin in the basal state and in patients and hamsters with islet cell tumors.
Topics: Acromegaly; Adenoma, Islet Cell; Adolescent; Adult; Animals; Child; Chromatography, Gel; Cricetinae; | 1971 |
Effects of glucose and other modifiers of insulin release on the oxidative metabolism of amino acids in micro-dissected pancreatic islets.
Topics: Alanine; Amino Acids; Animals; Arginine; Carbon Isotopes; Citrates; Cyclic AMP; Depression, Chemical | 1971 |
Transport and storage of 5-hydroxytryptamine in pancreatic -cells.
Topics: Animals; Biological Transport; Carbon Isotopes; Chromatography, Gel; Diazoxide; Glucose; Glyburide; | 1972 |
[Extragonadal endocrine manifestations of Klinefelter's disease].
Topics: Adrenal Gland Diseases; Adult; Antibodies; Autoantibodies; Blood Glucose; Diabetes Mellitus; Diazoxi | 1973 |
Diabetes: underlying biochemical lesions.
Topics: Diabetes Mellitus; Diazoxide; Epinephrine; Female; Growth Hormone; Humans; Hyperglycemia; Insulin; I | 1970 |
Calcium uptake by pancreatic -cells as measured with the aid of 45 Ca and mannitol- 3 H.
Topics: Animals; Biological Transport, Active; Calcium; Calcium Isotopes; Diazoxide; Dinitrophenols; Female; | 1971 |
[Antagonistic action of intestinal hormones and diazoxide on insulin secretion in humans].
Topics: Blood Glucose; Cholecystokinin; Diazoxide; Drug Antagonism; Fatty Acids, Nonesterified; Glucose; Gly | 1969 |
Levels of -ketoglutarate and glutamate in stimulated pancreatic -cells.
Topics: Animals; Carbutamide; Chemical Phenomena; Chemistry; Depression, Chemical; Diazoxide; Female; Fluoro | 1970 |
Uptake of alanine, arginine and leucine by mammalian pancreatic beta-cells.
Topics: Alanine; Animals; Arginine; Carbon Isotopes; Diazoxide; Fructose; Glucose; Glyburide; Hyperglycemia; | 1971 |
The effect of agents used in the treatment of bronchial asthma on carbohydrate metabolism and histamine sensitivity after beta-adrenergic blockade.
Topics: Adenine Nucleotides; Adrenal Cortex Hormones; Adrenalectomy; Alloxan; Aminophylline; Animals; Antige | 1970 |